A new approach to gene and cell therapy

United in Purpose

Build the technological and industrial infrastructure that will radically accelerate and scale the development of gene and cell therapy technologies and their translation to market.

NIVIRON — a new approach to gene therapy

NIVIRON is a next-generation biotechnology company developing gene and cell therapy technologies, with artificial intelligence intended for integration across scientific and business processes over time.

We work with fundamental biological mechanisms, building a systematic process for prototype generation followed by development, testing, and commercialization.

The company is building a scalable infrastructure based on the integration of computational modeling and laboratory validation. This is intended to accelerate the transition from scientific hypothesis to functional prototypes and solutions ready for commercialization.

At the center of the company is an infrastructure for creating technologies in the field of gene therapy, integrating two elements:

Digital infrastructure

Reproduces and automates key stages in the creation of new gene therapy technologies.

Laboratory base

Used for constructing prototypes and for testing their efficacy and safety.

Infrastructure for commercial development

Ensures that validated technological prototypes are advanced to the stage of clinical trials and subsequently licensed to Big Pharma.

Get in touch

If you are developing technologies in the field of gene therapy or looking for partners for collaborative research, feel free to reach out. 

Contact us

Privacy Policy

© 2025 Inc, Niviron,
All Rights Reserved.

Прокрутить вверх

Shapovalov Nikita

CEO

An entrepreneur with over 11 years of experience in creating and managing technology projects in biotechnology, digital health, and artificial intelligence.

 

Specializes in:
launching and developing projects at the preclinical stage,
IP licensing,

  • collaboration with universities and research institutions,
  • building R&D infrastructure,
  • securing funding,
  • preparing for grant and venture rounds.

Possesses hands-on experience in:

  • team formation,
  • market entry strategy development and implementation,
  • product packaging,
  • regulatory engagement.

Additional expertise includes:

  • AI and process automation in medicine,
  • development of digital solutions (mobile applications, patient portals, chatbots, mini apps),
  • strategic marketing and systematic sales in highly competitive niches.

Has access to a strong network of experts, investors, and contractors across the EU and US.

Capable of building projects from scratch to investment readiness, including comprehensive development of business models, scientific tracks, and market strategies.